News List

Mylan’s anti-retrovial drug Avonza approved in India


Avonza is a fixed-dose combinations recommended by the World Health Organization (WHO) as an alternative first-line regimen for people treated for HIV/AIDS.

By Team ABLE

Global biopharmaceutical company Mylan Pharmaceuticals Private Limited, a subsidiary of NASDAQ-listed Mylan N.V., has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza (TLE400).

Avonza is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg, recommended by the World Health Organization (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS.

Commenting on the launch, Mylan President Rajiv Malik said, “Developing Avonza and bringing it to patients with HIV in India is a continuation of our strong and sustained commitment to expanding access to affordable, high quality ARVs.”
In April 2017, the Health Ministry in India launched the Test and Treat Policy for HIV; anyone testing positive for HIV will get antiretroviral therapy irrespective of CD4 count or clinical stage.

Mylan believes that its Avonza is another step the company is taking to help India meet its Sustainable Development Goal of ending AIDS by 2030.